Vivimed Labs CFO Phaninder Nath P S Resigns Due to Health Issues

1 min read Updated on 06 Feb 2026, 05:45 PM

Reviewed by

Suketu GScanX News Team

Overview

Vivimed Labs Limited announced the resignation of Chief Financial Officer Mr. Phaninder Nath P S, effective February 06, 2026, due to personal health issues. The departure results in his cessation as Key Managerial Personnel and Senior Management Personnel. The company has complied with SEBI regulations by informing BSE and NSE about this key management change.

*this image is generated using AI for illustrative purposes only.

Vivimed Labs Limited has announced the resignation of its Chief Financial Officer, Mr. Phaninder Nath P S, effective February 06, 2026. The pharmaceutical company informed stock exchanges about this key management change through a regulatory filing under SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Resignation Details

The company disclosed that Mr. Phaninder Nath P S tendered his resignation due to personal health issues. In his resignation letter, he mentioned the need to undergo treatment for health problems that have been aggravating over the past few weeks.

Parameter:	Details
Reason for Change:	Personal health issues
Date of Resignation:	February 06, 2026
Date of Cessation:	February 06, 2026 (close of business hours)
Position:	Chief Financial Officer
Status:	Key Managerial Personnel & Senior Management Personnel

Regulatory Compliance

The resignation will result in Mr. Phaninder Nath P S ceasing to be Key Managerial Personnel under Section 203 of the Companies Act, 2013, and Senior Management Personnel under Regulation 30(5) of the SEBI Listing Regulations. This change affects his role in determining materiality of events or transactions for required stock exchange disclosures.

Vivimed Labs has fulfilled its regulatory obligations by notifying both BSE (Code: 532660) and NSE (Symbol: VIVIMEDLAB) about this development. The company provided all required details as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Management Transition

In his resignation letter, Mr. Phaninder Nath P S expressed gratitude to the Board for their support and cooperation during his tenure. He wished the company continued success in its future endeavors. The resignation letter was signed by Company Secretary Yugandhar Kopparthi on behalf of Vivimed Labs Limited.

The company has indicated it will initiate necessary filings with stock exchanges and the Ministry of Corporate Affairs as per applicable regulations. Vivimed Labs Limited, incorporated in 1988, operates from its registered office in Kolhar Industrial Area, Bidar, Karnataka, with corporate offices in Hyderabad, Telangana.

Vivimed Labs CFO and Company Secretary Receive CBI Notice After SBI Complaint on Financial Irregularities

1 min read Updated on 03 Feb 2026, 05:42 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Overview

Vivimed Labs Limited faces regulatory challenges as its Chief Financial Officer and Company Secretary have received official notices from the Central Bureau of Investigation. The notices follow a formal complaint filed by State Bank of India regarding financial irregularities, indicating serious concerns that require detailed examination by central investigative agencies.

*this image is generated using AI for illustrative purposes only.

Vivimed Labs Limited is facing increased regulatory scrutiny as its senior financial executives have come under the purview of a Central Bureau of Investigation inquiry. The pharmaceutical company's Chief Financial Officer and Company Secretary have received official notices from the CBI following formal complaints raised by State Bank of India regarding financial irregularities.

CBI Investigation Details

The Central Bureau of Investigation has issued notices to Vivimed Labs' Chief Financial Officer and Company Secretary as part of an ongoing investigation. The notices were served following a complaint filed by State Bank of India, which has raised specific concerns about financial irregularities involving the company.

Investigation Parameter:	Details
Investigating Agency:	Central Bureau of Investigation (CBI)
Complainant:	State Bank of India
Recipients of Notice:	Chief Financial Officer and Company Secretary
Nature of Complaint:	Financial Irregularities

Regulatory Implications

The involvement of the CBI in this matter indicates the serious nature of the financial irregularities that have been brought to light. When public sector banks file complaints with investigative agencies, it typically suggests significant concerns about financial compliance or potential irregularities that require detailed examination.

The formal complaint by State Bank of India adds weight to the investigation, as public sector banks maintain strict protocols before escalating matters to central investigative agencies.

Company Impact

This development places Vivimed Labs under regulatory spotlight, with its key financial executives now required to respond to the CBI's inquiries. The pharmaceutical company will need to address the concerns raised by State Bank of India regarding the alleged financial irregularities while cooperating with the ongoing investigation process.

The company's financial leadership team faces the challenge of managing both the investigation proceedings and maintaining operational continuity during this period of regulatory scrutiny.